Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment

Figures & data

Figure 1. Schematic diagram of the synthesis of PLGA-PEG-CBP prodrug.

Table 1. Characterization of drug-loaded NPs.

Samples	Particle size (nm)	PDI	Zeta potential (mV)	EEPTX (%)
PTX NPs	88.2 ± 2.7	0.09 ± 0.01	−6.5 ± 0.9	86.5 ± 2.7
CBP NPs	116.3 ± 3.5	0.12 ± 0.03	−3.8 ± 0.6	/
PTX/CBP NPs	125.1 ± 3.9	0.14 ± 0.04	−5.1 ± 0.8	85.4 ± 2.2

Figure 2. In vitro PTX release profile of PTX/CBP NPs and PTX NPs.

Figure 3. In vitro CBP release profile of PTX/CBP NPs and CBP NPs.

Table 2. IC₅₀ of drug-loaded NPs and drug solutions.

Drug solutions	IC50 of PTX (μM)	IC50 of CBP (μM)
PTX solution	3.78 ± 0.39	/
CBP solution	/	4.87 ± 0.41
PTX NPs	1.12 ± 0.16	/
CBP NPs	/	1.74 ± 0.21
PTX/CBP NPs	0.38 ± 0.06	0.76 ± 0.08

Figure 4. In vivo anticancer efficacy presented as tumor volume changes after treatment with PTX/CBP NPs, CBP NPs, PTX NPs, CBP solution, PTX solution and 0.9% saline control in NCL-H460 tumor-bearing BALB/c nude mice models.